{
    "clinical_study": {
        "@rank": "129467", 
        "arm_group": [
            {
                "arm_group_label": "rhBNP Group", 
                "arm_group_type": "Experimental", 
                "description": "Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours."
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effects of rhRNP on urine output and\n      hemodynamics following corrective repair of Tetralogy Of Fallot."
        }, 
        "brief_title": "Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot", 
        "condition": [
            "Congenital Heart Defects", 
            "Tetralogy Of Fallot"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Defects, Congenital", 
                "Tetralogy of Fallot"
            ]
        }, 
        "detailed_description": {
            "textblock": "CVP(central venous pressure) and cardiac output are serious index in children with Tetralogy\n      Of Fallot after the corrective repair.The purpose of this study is to investigate if the\n      therapy of rhRNP can improve the survival and life quality after the corrective repair of\n      Tetralogy Of Fallot."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent obtained from patient's legally acceptable representative.\n\n          -  Pediatric patients after Repair of Tetralogy Of Fallot.\n\n        Exclusion Criteria:\n\n          -  Psychotic, addictive or other disorder limiting the ability to provide informed\n             consent or to comply with study requirements.\n\n          -  Treatment or planned treatment with another investigational drug within 3 months of\n             screening.\n\n          -  Known hypersensitivity to bosentan or any of the excipients\n\n          -  cardiogenic shock and inclination of hypotension\uff08SBP< 60mmHg\uff09."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941576", 
            "org_study_id": "SJTUMS-20130903"
        }, 
        "intervention": [
            {
                "arm_group_label": "rhBNP Group", 
                "description": "Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.", 
                "intervention_name": "recombinant human brain natriuretic peptide (rhBNP)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "description": "Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.", 
                "intervention_name": "Placebo (0.9% sodium chloride)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Natriuretic Peptide, Brain"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart defects, Congenital", 
            "rhBNP", 
            "heart failure"
        ], 
        "lastchanged_date": "September 9, 2013", 
        "location": {
            "contact": {
                "email": "zmxyfb@aliyun.com", 
                "last_name": "Zhuoming Xu, MD PhD", 
                "phone": "86213501699158"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200127"
                }, 
                "name": "Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center, Medical college of Shanghai Jiaotong University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot", 
        "overall_official": {
            "affiliation": "Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center", 
            "last_name": "Zhuoming Xu, MD,PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "we will evaluate the cardiac function through the consecutive changed numerical value of brain natriuretic peptide and Central Venous Pressure.", 
            "measure": "Changes from Baseline in BNP and CVP after the infusion of rhBNP", 
            "safety_issue": "No", 
            "time_frame": "12 months after operation of Tetralogy Of Fallot"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941576"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Xu Zhuoming", 
            "investigator_title": "Vice Chief, Department of thoracic and cardiovascular surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "we evaluate the renal function through the volume of urine out and numerical value of serum creatinine and blood urea nitrogen.", 
            "measure": "Changes from baseline on the volume of urine out and numerical value of serum creatinine and blood urea nitrogen", 
            "safety_issue": "No", 
            "time_frame": "12 months after operation of Tetralogy Of Fallot"
        }, 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}